These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 14684678)

  • 1. Novel cardiovascular risk factors in end-stage renal disease.
    Zoccali C; Mallamaci F; Tripepi G
    J Am Soc Nephrol; 2004 Jan; 15 Suppl 1():S77-80. PubMed ID: 14684678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease.
    Zoccali C
    Blood Purif; 2002; 20(5):469-72. PubMed ID: 12207095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease.
    Testa A; Spoto B; Tripepi G; Mallamaci F; Malatino L; Fatuzzo P; Maas R; Boeger R; Zoccali C
    J Hypertens; 2005 Oct; 23(10):1825-30. PubMed ID: 16148605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?
    Kielstein JT; Zoccali C
    Am J Kidney Dis; 2005 Aug; 46(2):186-202. PubMed ID: 16112037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients.
    Kumagai H; Sakurai M; Takita T; Maruyama Y; Uno S; Ikegaya N; Kato A; Hishida A
    Am J Kidney Dis; 2006 Nov; 48(5):797-805. PubMed ID: 17059999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease.
    Osanai T; Nakamura M; Sasaki S; Tomita H; Saitoh M; Osawa H; Yamabe H; Murakami S; Magota K; Okumura K
    Kidney Int; 2003 Dec; 64(6):2291-7. PubMed ID: 14633154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical epidemiology of major nontraditional risk factors in peritoneal dialysis patients.
    Zoccali C; Enia G; Tripepi G; Panuccio V; Mallamaci F
    Perit Dial Int; 2005 Feb; 25 Suppl 3():S84-7. PubMed ID: 16048265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach.
    Ravani P; Tripepi G; Malberti F; Testa S; Mallamaci F; Zoccali C
    J Am Soc Nephrol; 2005 Aug; 16(8):2449-55. PubMed ID: 15944335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule.
    De Gennaro Colonna V; Bianchi M; Pascale V; Ferrario P; Morelli F; Pascale W; Tomasoni L; Turiel M
    Med Sci Monit; 2009 Apr; 15(4):RA91-101. PubMed ID: 19333216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.
    Ueda S; Yamagishi SI; Matsumoto Y; Fukami K; Okuda S
    Clin Exp Nephrol; 2007 Jun; 11(2):115-121. PubMed ID: 17593510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kidney disease as an independent risk factor for cardiovascular events.
    Kumar J; Shah SV
    J Ren Nutr; 2005 Jan; 15(1):99-104. PubMed ID: 15648016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiovascular events in chronic advanced renal insufficiency. Current concepts].
    Zoccali C
    Recenti Prog Med; 2003 Mar; 94(3):125-30. PubMed ID: 12677780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
    Böger RH; Bode-Böger SM
    Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
    Busch M; Fleck C; Wolf G; Stein G
    Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.
    Böger RH
    Vasc Med; 2005 Jul; 10 Suppl 1():S19-25. PubMed ID: 16444865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
    Böger RH
    Cardiovasc Res; 2003 Oct; 59(4):824-33. PubMed ID: 14553822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure.
    Nanayakkara PW; Teerlink T; Stehouwer CD; Allajar D; Spijkerman A; Schalkwijk C; ter Wee PM; van Guldener C
    Kidney Int; 2005 Nov; 68(5):2230-6. PubMed ID: 16221223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease.
    van Guldener C; Nanayakkara PW; Stehouwer CD
    Clin Chem Lab Med; 2007; 45(12):1683-7. PubMed ID: 17937610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hyperphosphatemia and cardiovascular risk in patients on dialysis].
    Basić-Jukić N; Kes P
    Acta Med Croatica; 2004; 58(3):207-13. PubMed ID: 15503684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular calcification in end-stage renal disease.
    Salusky IB; Goodman WG
    Nephrol Dial Transplant; 2002 Feb; 17(2):336-9. PubMed ID: 11812902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.